Compass Therapeutics (CMPX) Capital Expenditures (2019 - 2026)
Compass Therapeutics recorded quarterly Capital Expenditures of $82000.0 in Q1 2026, up 1071.43% quarter-over-quarter from $7000.0 in Q3 2025, and up 355.56% year-over-year from $18000.0 in Q1 2025.
Compass Therapeutics' Capital Expenditures history runs 8 years deep, the most recent figure standing at $82000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 355.56% year-over-year to $82000.0; the TTM figure through Mar 2026 stood at $89000.0 (up 43.55% YoY), while the FY2025 annual figure was $25000.0, down 43.18% from the prior year.
- Capital Expenditures came in at $82000.0 for Q1 2026 at Compass Therapeutics, up from $7000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $194000.0 in Q1 2022 to a low of -$63000.0 in Q2 2022.
- A 5-year average of $35727.3 and a median of $18000.0 in 2025 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures slumped 123.95% in 2022 and surged 355.56% in 2026, its largest moves.
- Compass Therapeutics' Capital Expenditures stood at $54000.0 in 2022, then tumbled by 83.33% to $9000.0 in 2023, then jumped by 388.89% to $44000.0 in 2024, then slumped by 84.09% to $7000.0 in 2025, then soared by 1071.43% to $82000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $82000.0, $7000.0, and $18000.0 for Q1 2026, Q3 2025, and Q1 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | 82,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 82,000.00 |
| Mar 31, 2026 | 82,000.00 |
| Sep 30, 2025 | 7,000.00 |
| Sep 30, 2025 | 7,000.00 |
| Mar 31, 2025 | 18,000.00 |
| Mar 31, 2025 | 18,000.00 |
| Sep 30, 2024 | 44,000.00 |
| Sep 30, 2024 | 44,000.00 |
| Dec 31, 2023 | 9,000.00 |
| Dec 31, 2023 | 9,000.00 |
| Sep 30, 2023 | 10,000.00 |
| Sep 30, 2023 | 10,000.00 |
| Jun 30, 2023 | 11,000.00 |
| Jun 30, 2023 | 11,000.00 |
| Dec 31, 2022 | 54,000.00 |
| Dec 31, 2022 | 54,000.00 |
| Sep 30, 2022 | 27,000.00 |
| Sep 30, 2022 | 27,000.00 |
| Jun 30, 2022 | -63,000.00 |
| Jun 30, 2022 | -63,000.00 |
| Mar 31, 2022 | 194,000.00 |
| Mar 31, 2022 | 194,000.00 |
| Dec 31, 2021 | 777,000.00 |
| Dec 31, 2021 | 777,000.00 |
| Sep 30, 2021 | 367,000.00 |
| Sep 30, 2021 | 367,000.00 |
| Jun 20, 2021 | 263,000.00 |
| Jun 20, 2021 | 263,000.00 |
| Mar 31, 2021 | 161,000.00 |
| Mar 31, 2021 | 161,000.00 |
| Sep 30, 2020 | 23,000.00 |
| Sep 30, 2020 | 23,000.00 |
| Jun 30, 2020 | 16,000.00 |
| Jun 30, 2020 | 16,000.00 |
| Mar 31, 2020 | 12,000.00 |
| Mar 31, 2020 | 12,000.00 |
| Sep 30, 2019 | 281,000.00 |
| Sep 30, 2019 | 281,000.00 |
| Jun 30, 2019 | 254,000.00 |
| Jun 30, 2019 | 254,000.00 |